News

Video

Triple Combination Therapies in RCC: Clinical Trial Insights

Author(s):

Ulka Vaishampayan, MDAlan Tan, MD

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Related Videos
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Viktor Grünwald, MD, PhD
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Timothy Yap, MBBS, PhD, FRCP
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
Timothy Yap, MBBS, PhD, FRCP
Sumanta Kumar Pal, MD, FASCO,
A panel of 5 experts on lung cancer
Related Content
David A. Braun, MD, PhD
June 10th 2024

Braun Spotlights Novel Treatment Developments in RCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

David A. Braun, MD, PhD
June 7th 2024

Braun Highlights Advances in RCC Treatment Paradigm, Looks Towards Future

Elias Jabbour, MD, professor, medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
April 8th 2024

FDA Approval Insights: Ponatinib in Ph+ ALL

Brian Rini, MD
June 5th 2024

Higher T-Cell Inflamed GEP Values Are Positively Associated with Outcomes For Pembrolizumab/Axitinib in ccRCC

Jens Hoeppner, FAChirg, FACS, MD
June 5th 2024

Lenvatinib Plus Pembrolizumab Delays Tumor Progression in All Organs vs Sunitinib in Advanced RCC